Regulatory approval

Published by the Health Canada. Approved

KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS >= 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.

This is written in the approval document.

Citation

Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083378.PDF. Published January 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals